Phase 3 N=156 Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)
Neurocysticercosis · Epilepsy
Primary: PK Substudy - Area Under the Curve of Albendazole in Treatment in Day 1 — 1412.2; 1111 ng*h/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=7 Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria
Seizure · Epilepsy · Cerebral Malaria
Primary: Freedom From Seizure — 7 individuals
Phase 2 N=10 Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid
Pharmacokinetics
Primary: Unbound Ceftolozane Exposure in the Plasma — 322.6 mg*h/L
Phase 4 N=10 Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis
Infantile Neronal Ceroid Lipofuscinosis
Primary: Change in Cellular Granular Osmiophilic Deposits (GRODs) in Electron Micrographs of Peripheral White Blood Cells. — -0.3317 Average number of GRODs
N/A N=231 Lumbar Puncture and Syphilis Outcome
Syphilis
Primary: Appropriate Decline in Serum Rapid Plasma Reagin Test (RPR) Titer — 38; 30 Participants — p=0.29
N/A N=60 Neocortical Epilepsies - Do They Progress?
Epilepsy
Primary: Functional Connectivity
Phase 2 N=44 A Safety and Feasibility Study of Enteral LVT vs. Standard of Care for Seizure Control in Pediatric CM
Seizure · Epilepsy · Cerebral Malaria
Primary: Minutes With Seizure on EEG — 165.2; 464.8 minutes with seizure
N/A N=31 Cognitive Effects of Treatment of Interictal Discharges
Epilepsy
Primary: Mean Change in Focal Interictal Discharges (IEDs) Per Hour, Pre to Post Treatment — -28.8; .54 IEDs/hour — p=>0.05
Phase 2 N=20 Effect of Cenicriviroc on HIV Neurocognitive Impairment
AIDS Dementia Complex · HIV-1-Associated Cognitive Motor Complex · Human Immunodeficiency Virus
Primary: Change From Baseline to Week 24 in Global Neuropsychological Performance — .24 units on a scale — p=0.0079
Phase 3 N=87 Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age
Chagas Disease
Primary: Global PCR (Conventional PCR and Real-time Quantitative PCR) Immediately After the End of Treatment. — 16; 20 Participants
Phase 1 N=60 Praziquantel Bioequivalence Study
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of L-Praziquantel (L-PZQ) — 441.53; 547.41; 460.25 Hour*nanogram…
Phase 3 N=57 Treating Brain Swelling in Pediatric Cerebral Malaria
Malaria, Cerebral
Primary: Number of Participants Who Died — 5; 5; 5 Participants
N/A N=20 EEG Cap for Identification of Non-Convulsive Status Epilepticus
Nonconvulsive Status Epilepticus · Subclinical Seizure · Altered Mental Status
Primary: Time Difference Between EEG Cap and Standard EEG Results Reporting — 103.4 minutes — p=0.0005
Phase 1 N=36 Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers
Healthy
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-inf) Adj of L-Praziquantel (L-PZQ) After Dose Adjustment — 825.2; 2066.0; 216.7…
Phase 4 N=4 Treatment of CNS Sarcoidosis With H.P. Acthar Gel
CNS Sarcoidosis
Primary: Karnofsky Performance Status (KPS) Score — 76.67; 76.67 score on a scale — p=1.0
Phase 2 N=74 Intravenous Lacosamide Compared With Fosphenytoin in the Treatment of Patients With Frequent Nonconvulsive Seizures
Nonconvulsive Seizures
Primary: Percentage of Subjects Who Experience no Nonconvulsive Seizures (NCS) for 24 Hours Following Treatment With LCM vs. fPHT, as Measured by Continuous…